Next Earnings date is expected on
08/03/2021
Pacira BioSciences (PCRX) has an average rating of outperform and price targets ranging from $54 to $94, according to analysts polled by Capital IQ. (MT...
Pacira BioSciences (PCRX) reported Tuesday preliminary unaudited Q2 revenue of $135.6 million. Analysts polled by Capital IQ had projected Q2 sales of...
Pacira BioSciences (PCRX) said Tuesday it has entered into a distribution agreement with Eurofarma Laboratories for the development and commercialization...
On Jun 08, 2021, Dr Donald C Manning, Chief Medical Officer, reported a sale of 2,600 shares in Pacira Biosciences (PCRX) for $158,964. Following the Form...
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 06/17/2021 8-K |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| Chief Financial Officer | Charles A. Reinhart |
| Chief Medical Officer | Roy Winston |
| Chief Technical Officer | Charles Anthony Laranjeira |
| Price Open | $59.61 |
| Previous Close | $60.08 |
| 52 Week Range | $48.23 - 80.00 |
| Market Capitalization | $2.6 B |
| Shares Outstanding | 44.0 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 08/03/2021 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 17.76 |
| Earnings per Share | $3.55 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | 33.35% |
| Return on Equity | 26.34% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
